Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alveavax-v1.2 Booster in Healthy Adults
NCT05844202Phase 1Completed
- Sponsor
- Telis Bioscience
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alveavax in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Telis Bioscience. Primary endpoint: Safety and tolerability of Alveavax-v1.2 in healthy participants compared to a control booster vaccine at Day 7. Started Jun 2022; status: completed.
02
Drugs
alveavax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05844202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844202.